Analysis

Bristol-Myers' $74B Celgene Buy Gives 2019 M&A Fast Start

By Chelsea Naso (January 3, 2019, 7:16 PM EST) -- Deal-making roared just three days into the New Year as Bristol-Myers Squibb's $74 billion cash-and-stock megadeal for biopharmaceutical company Celgene carried a price tag bigger than last year's largest deal despite recent market volatility.

The deal, announced Thursday, will see Bristol-Myers Squibb, represented by Kirkland & Ellis LLP, snap up Celgene Corp., advised by Wachtell Lipton Rosen & Katz, in an effort to build a top cancer, inflammatory and immunologic disease and cardiovascular biopharmaceutical player.

Under the terms of the transaction, each Celgene share will be swapped for one Bristol-Myers Squibb share, $50 in cash and one tradeable contingent value right...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!